Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology | Psychiatry/Psychology | Pediatrics/Neonatology | Family Medicine
 Disease Category: Attention Deficit/Hyperactivity Disorder (ADHD - Pediatric)
Location: United States, UT

Trial Information

Adolescent ADHD

A Phase 3b, Double-blind, Randomized, Active-controlled, Parallel-group Study to Compare the time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD) who have Had an Inadequate response to Methylphenidate Therapy.

Patient Inclusion Criteria:

  • Historical or current inadequate response to MPH treatment
  • Male or Female aged 6-17 years

Patient Exclusion Criteria:

  • Subject has taken >1 MPH treatment
  • Subject has previously demonstrated intolerable side effects to 1 or more MPH Treatments
  • Subject has previously been exposed to Strattera or to amphetamine therapy

Cher Struck, Director Marketing and Recruiting
Lifetree Clinical Research
3838 South 700 East Suite 202
Salt Lake CIty, UT 84106
Phone: 801-269-8200
Email: chers@lifetreeresearch.com

View Map

Research Center Information: Lifetree Clinical Research

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:  
Message:
 

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.